FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:821-822 March 16, 2000 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mayeux, R. Related Article by Mayeux, R.

To the Editor: In their article on the treatment of Alzheimer's disease (Nov. 25 issue),¹ Mayeux and Sano failed to mention AIT-082 (leteprinim potassium, Neotrofin), galantamine, or lazabemide but included such dubious treatments as Gingko biloba and acetyl-l-carnitine. Furthermore, the inclusion of metrifonate, rivastigmine, and eptastigmine, all of which are cholinesterase inhibitors not yet available in the United States, and the omission of huperzine A were puzzling indeed. Huperzine A, a Chinese herb, is a reversible cholinesterase inhibitor like tacrine and donepezil,² but it may be more effective than either of those drugs. In fact, it may bind to cholinesterase . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.